Staff Directory

Filter By Surname
Filter By Position
Filter By Keyword
Filter By Cancer Type
Search
Professor Andrejs Braun
Professor of Genome Regulation Director of Education

My group is interested in epigenetic regulation of somatic mutagenesis in normal and malignant B cells. We aim to understand how alterations in the nuclear envelope influence B cell chromatin conformation, and what the epigenetic consequences of these alterations are.

Dr Gabriella Ficz
Reader in molecular biology and epigenetics

My group aims to discover the epigenetic changes taking place during cancer initiation and develop potential drugs that can prevent these changes which may be abnormal but reversible, before many damaging mutations occur.

Professor Jude Fitzgibbon
Honorary Professor

My research group works on molecular pathology, genetics and progression of leukaemia and lymphomas, aiming to improve on current diagnostic, prognostic and treatment strategies.

Dr Rifca Le Dieu
Clinical Reader

I am the Module Lead for 3 undergraduate Biomedical Science Modules. I am also the Cancer Theme Lead for MBBS with direct responsibility for Year 2 Cancer Week. In addition, I supervise MSc project dissertations.

Professor Jessica Okosun
Professor of Translational Cancer Research

My research focuses on understanding the genetic and molecular mechanisms that underlie the initiation and progression of B-cell non-Hodgkin’s lymphomas in order to define clinically-relevant biomarkers.

Dr Kevin Rouault-Pierre
Reader in Stem Cell Biology and Disease

My main research interests are in haematopoietic stem cells (HSCs) and leukemic initiating cells. I seek to understand how intrinsic and extrinsic signals are integrated by normal and malignant stem cells.

Dr Findlay Redvers Bewicke-Copley

My work is currently focused on lymphoma, working on variant calling and gene expression analysis of NGS data.

Dr Arantxa Carrasco Leon

My research project aims to identify germline mutations in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) and to understand their contribution in the development of these haematological diseases, using in vitro and ex vivo models. This study will lead to a step forward in the diagnosis and treatment of this group of life-threatening diseases.

Dr Marta Crespi-Sallan

My research is focused on describing the mechanisms underlying Lamin B1 nuclear disassembly in B-cell normal development and how a dis-regulated Lamin B1 removal pathway could lead to several haematological malignancies within the germinal centre in secondary lymph organs.

Dr Lou Salome Herman

My current research focuses on investigating B and T cell population differences in chronic lymphocytic leukaemia (CLL) mouse models before and after Bruton Tyrosine Kinase (BTK) inhibitor treatments.

Dr Amanda Jimenez-Pompa

I am interested in unveiling and modelling the mechanisms that drive clonal haematopoiesis and exploring niche-based therapies to prevent it, as clonal haematopoiesis has been recently linked to an increase in the development of leukaemia and cardiovascular conditions.

Dr Sandra M. Martin-Guerrero

My work is focused on exploiting cell cycle vulnerabilities in tumour cells, particularly the role of MASTL or Greatwall kinase in cell cycle control. My research will explore the role of MASTL in AML and whether it could be a new therapeutic target in this disease.

Dr Megha Meena

We use novel mass cytometry technology following allogeneic haematopoietic stem-cell transplantation in patients, to define the global landscape of immune-cell populations preceding development of acute graft-versus-host disease (aGvHD) and to identify a dominant immunoregulatory role for subsets of CD56hi NK cells in limiting alloreative T-cell expansion and aGvHD.

Dr Ana Rio-Machin

My research project aims to identify germline mutations in families with leukaemia of unknown aetiology and study the intra and inter leukaemia heterogeneity observed in these families, through examination of clonal evolution and secondary genetic events.

Dr Mike Williams

My research focusses on understanding cancer-specific metabolism in acute myeloid leukaemia and targeting this metabolism to overcome therapeutic resistance. I also explore the role of diet and obesity in leukaemogenesis and response to therapy.